Nippon Steel plans to raise up to $5.6 billion in subordinated loans, as part of efforts to strengthen its balance sheet following its $14 billion acquisition of U.S. Steel.

INmune Bio's XPro shows promise in early AD despite missed endpoints. Click here to find out why I rate INMB stock is a Hold.